Salomon-Montavon N A, Burger A G
J Endocrinol Invest. 1984 Oct;7(5):501-5. doi: 10.1007/BF03348457.
Bromocriptine, because of its dopaminergic activity, could possibly inhibit TSH secretion. This hypothesis was tested in 7 normal male volunteers. Thyroid function was suppressed with the very potent thyromimetic analogue, 3'isopropyl-3,5-diiodo-L-thyronine (DIIP). We wanted to observe, after stopping this treatment, whether the return of serum T3, T4, rT3 and TSH values was influenced by concomitant bromocriptine treatment (5 mg/day). For comparison, the DIIP study was also performed without bromocriptine treatment. In both cases, serum T4 and serum T3, which had decreased by, respectively, 34% +/- 5% and 17% +/- 5%, returned over the same time interval to their initial values. Serum TSH and TRH-mediated TSH secretion were also unaffected by the bromocriptine treatment. DIIP does not interfere in the serum determination of T3, T4 and rT3. During suppression with DIIP serum T3 fell less than serum T4 and returned more rapidly to its initial concentrations. It is concluded that dopaminergic inhibition by bromocriptine, at this dose, is insufficient to alter normal thyroid function. In addition, during suppression and shortly thereafter there is a tendency for the serum T3 levels to be maintained.
由于溴隐亭具有多巴胺能活性，它可能会抑制促甲状腺激素（TSH）的分泌。该假设在7名正常男性志愿者身上进行了验证。使用强效的甲状腺模拟类似物3'-异丙基-3,5-二碘-L-甲状腺原氨酸（DIIP）抑制甲状腺功能。我们想观察在停止这种治疗后，血清三碘甲状腺原氨酸（T3）、甲状腺素（T4）、反三碘甲状腺原氨酸（rT3）和促甲状腺激素（TSH）值的恢复是否会受到同时使用溴隐亭治疗（5毫克/天）的影响。为作比较，还进行了未使用溴隐亭治疗的DIIP研究。在这两种情况下，分别下降了34%±5%和17%±5%的血清T4和血清T3在相同的时间间隔内恢复到了初始值。血清TSH以及促甲状腺激素释放激素（TRH）介导的TSH分泌也不受溴隐亭治疗的影响。DIIP不干扰血清中T3、T4和rT3的测定。在用DIIP抑制期间，血清T3的下降幅度小于血清T4，并且恢复到初始浓度的速度更快。得出的结论是，在此剂量下，溴隐亭的多巴胺能抑制作用不足以改变正常的甲状腺功能。此外，在抑制期间及之后不久，血清T3水平有维持的趋势。
